CDMRP: Melanoma Research Program (MRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Congressionally Directed Medical Research Programs (CDMRP) released a pre-announcement for anticipated FY26 Melanoma Research Program (MRP) funding opportunities. This notice signals that new award mechanisms and funding will be forthcoming, but the application deadlines are not yet specified; they will be published in the formal Funding Opportunity Announcement (FOA) on Grants.gov and eBRAP once available.

How much funding would I receive?

• Idea Award: Maximum total costs up to $560,000 (period up to 2 years).

• Melanoma Academy Scholar Award: Maximum total costs up to $770,000 (period up to 3 years).

• Team Science Award: Maximum total costs up to $2.1 million (period up to 3 years).

• Focused Program Award – Rare Melanomas: Maximum total costs up to $2.8 million (period up to 4 years).

• Survivorship Research Award: Maximum total costs up to $1.015 million (period up to 3 years).

What could I use the funding for?

• All awards must address one or more of the FY26 MRP focus areas:

  • Identify, understand, and mitigate melanoma risk factors and develop biomarkers.

  • Develop detection/diagnosis technologies that improve risk stratification.

  • Define mechanisms of initiation, response/resistance to therapy, progression, recurrence, metastasis.

  • Develop new preclinical models representing disease evolution (cutaneous and rare subtypes).

  • Address unmet needs across cancer research spectrum for rare melanomas.

  • Address psychological/social impacts, quality of life, treatment toxicities, and survivorship issues.

Are there any additional benefits I would receive?

• Melanoma Academy Scholar Award includes mentoring, national networking, and structured career support.

What is the timeline to apply and when would I receive funding?

• The pre-announcement is available now (released February 18, 2026); full FOAs will be released later on Grants.gov.

• Exact pre-application and application deadlines will be specified in those FOAs—not yet provided in the pre-announcement.

• Funding start dates will depend on the FOA timeline and award negotiations—not specified in the pre-announcement.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (MRDC) under the CDMRP.

Who is eligible to apply?

Eligibility for each award mechanism is defined in the full FOA. From the pre-announcement:

• Idea Award: Investigators at or above the postdoctoral level (or equivalent).

• Melanoma Academy Scholar Award: Investigators within 7 years of first faculty appointment.

• Team Science Award: Independent investigators (Assistant Professor level or equivalent).

• Focused Program Award – Rare Melanomas: Initiating PI at Associate Professor level or equivalent; Partnering PIs at Assistant Professor level or above.

• Survivorship Research Award: Independent investigators (Assistant Professor level or equivalent).

Detailed eligibility criteria (organization types, citizenship, cost share, etc.) will be in the FOA—not specified in the pre-announcement.

What companies and projects are likely to win?

Not specified in the pre-announcement; CDMRP typically funds high-risk, high-gain research that aligns tightly with the listed focus areas and relevance to melanoma biology, detection, survivorship, and unmet clinical needs. Projects that integrate multidisciplinary approaches or include military/VA relevance are typically competitive, but the solicitation does not provide explicit criteria.

Are there any restrictions I should know about?

• The pre-announcement states that submission does not guarantee FOAs or funding.

• All applications must adhere to the final FOA instructions on Grants.gov when released.

• Preliminary data expectations, animal or human subjects requirements, and allowable costs will be defined in the FOA—not yet specified here.

How long will it take me to prepare an application?

• Not specified in the pre-announcement because deadlines are not yet posted. Generally, planning should begin now given the complexity of CDMRP submissions and required pre-applications (e.g., eBRAP).

How can BW&CO help?

BW&CO can:

• Monitor the release of the official FOA and deadlines.

• Translate the FOA into a targeted application strategy.

• Help craft compelling project narrative, budget, and compliance sections.

• Provide review, editing, and submission support to maximize competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Multiple Sclerosis Research Program (MSRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP Multiple Sclerosis Research Program (MSRP) Pre-Announcement for FY26 provides early notice of anticipated funding opportunities for innovative research on multiple sclerosis. This announcement is not the official funding solicitation — it is intended to give investigators advance insight to begin planning competitive proposals. Final Funding Opportunity Announcements (FOAs) with submission deadlines will be posted later on Grants.gov and eBRAP.

How much funding would I receive?

The MSRP pre-announcement outlines proposed award types with maximum allowable funding levels (total costs, including direct and indirect):

• Clinical Trial Award
  • Level 1: up to $1,000,000 over up to 3 years
  • Level 2: up to $2,000,000 over up to 4 years

• Early Investigator Research Award
  • Up to $300,000 over up to 2 years

• Exploration – Hypothesis Development Award
  • Up to $250,000 over up to 2 years

• Investigator-Initiated Research Award
  • Up to $1,000,000 over up to 3 years

These amounts represent maximums anticipated for each mechanism; they are not guaranteed awards until the official FOA is released.

What could I use the funding for?

Funding is intended to support multiple sclerosis research, across a variety of scientific aims depending on award mechanism. Key areas include:

Clinical Trial Award

• Conduct proof-of-principle or early-phase clinical trials with potential to improve clinical outcomes or inform translational feasibility.

• Research must focus on treatment approaches or evidence relevant to MS patient populations.

Early Investigator Research Award

• Support early-career investigators initiating MS research.

• Projects may explore CNS repair, protection, regeneration, correlates of disease activity, symptomatic measurements, or disease mechanisms.

Exploration – Hypothesis Development Award

• Support high-risk, high-gain conceptual studies, not clinical trials.

• Encourages innovative ideas across MS biology, disease progression, symptoms, and repair.

Investigator-Initiated Research Award

• Support rigorous, investigator-driven MS studies with strong preliminary data.

• Applies to new and established researchers; clinical trials are excluded.

Are there any additional benefits I would receive?

• This pre-announcement gives lead time to plan research concepts and collaborations ahead of official FOA release.

• Investigators can prepare strategic proposals, letters of intent, and consortium plans before deadlines are published.

• Awardees likely benefit from CDMRP’s two-tier review process aligning scientific merit with program relevance.

What is the timeline to apply and when would I receive funding?

• Application deadlines will not be in this pre-announcement.
  The CDMRP plans to release full FOAs on Grants.gov and eBRAP with specific pre-application and application due dates.

• Funding decisions and award issuance will occur after review of submitted applications (typically several months after the final due date, depending on CDMRP schedule and appropriations).

Where does this funding come from?

The MSRP is funded through the Department of Defense Congressionally Directed Medical Research Programs (CDMRP), which received appropriations as part of the FY26 Defense Appropriations Act. The CDMRP oversees research across many disease areas, including multiple sclerosis.

Who is eligible to apply?

Eligibility varies by award mechanism, but generally:

• Clinical Trial Award: Independent investigators at all career levels.

• Early Investigator Research Award: Early stage investigators (mentored; specific experience requirements).

• Exploration and Investigator-Initiated Awards: Independent investigators at all career stages; specific criteria on prior funding or experience may apply.

Final eligibility details will be in the official FOA.

What companies and projects are likely to win?

Projects likely to be competitive will:

• Align strongly with MSRP focus areas (repair, neuroprotection, symptom biology, clinical intervention).

• Demonstrate rigorous methods, clear impact, and feasibility.

• Include strong preliminary data (where required).

• Address CDMRP priorities in multiple sclerosis research.

Are there any restrictions I should know about?

• The pre-announcement is not a funding solicitation — award cannot be applied for until FOAs are released.

• Clinical trials must meet relevant definitions and follow regulatory requirements.

• Some award types exclude clinical trials or have career stage restrictions.

How long will it take me to prepare an application?

• Planning ahead based on this pre-announcement is recommended.

• Actual FOA publication will define exact due dates, which determine preparation time.

• Early strategic planning (e.g., consortium building, preliminary data generation, letters of intent) will speed application development.

How can BW&CO help?

If you’re seeking professional proposal support, experts like BW&CO Consulting can help you:

• Interpret the pre-announcement and upcoming FOA

• Identify optimal award mechanisms

• Plan research strategy and draft proposals

• Prepare budgets and compliance documents

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Tuberous Sclerosis Complex Research Program (TSCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP has issued a pre-announcement for anticipated Fiscal Year 2026 TSCRP funding opportunities to support high-impact research in Tuberous Sclerosis Complex (TSC). This early notice gives researchers time to plan and refine ideas. The full Funding Opportunity Announcement (FOA), including deadlines and submission details, will be posted on Grants.gov in the coming weeks. Investigators should not interpret this pre-announcement as a funding guarantee.

How much funding would I receive?

While exact award amounts are not official until FOAs are posted, the TSCRP pre-announcement outlines three mechanisms with indicative elements:

1. Clinical Translational Research Award

• Supports studies that move promising research closer to clinical application.

• Includes potential pilot clinical trials, biomarker development, and clinical endpoint work.

• Eligible PIs include independent investigators and advanced practice clinical personnel (e.g., genetic counselors, nurses) for clinical care-focused proposals.

• Maximum duration: 3 years

• Estimated total costs: up to ~$1.6M single PI / ~$1.9M with Partnering PI option (pending FOA).

2. Exploration – Hypothesis Development Award

• For high-risk, high-gain ideas in early stages.

• Study designs must be innovative but do not necessarily require preliminary data.

• Clinical subject work must meet human-subjects protection requirements.

• Maximum duration: 2 years

• Estimated total costs: up to ~$350K (pending FOA).

3. Idea Development Award

• Supports new or cross-disciplinary ideas with preliminary data.

• Includes specific options for new-to-field investigators transitioning into TSC research.

• Maximum duration: 3 years

• Estimated total costs: up to ~$800K (pending FOA).

Note: These figures and durations are as presented in the pre-announcement and may differ slightly in the final FOA.

What could I use the funding for?

Applications must address at least one of the following TSCRP priorities:

• Neuropsychiatric aspects of TSC: Understanding, preventing, and treating TSC-associated neuropsychiatric disorders (e.g., behavioral, pharmacological, surgical interventions).

• Tumors and cysts: Preventing or eradicating TSC-related tumors such as angiomyolipomas, subependymal giant cell astrocytoma (SEGA), and lymphangioleiomyomatosis (LAM), including mechanistic insights into TSC signaling pathways.

• Epilepsy associated with TSC: Prevention, improved treatment, and mitigation of adverse neurodevelopmental outcomes.

• Diagnostic & therapeutic technologies: Development or testing of tools and technologies that improve clinical outcomes in TSC.

• Maternal-fetal & reproductive health in TSC: Mechanisms or care improvements affecting women with TSC or LAM and their infants.

Are there any additional benefits I would receive?

FY26 SCIRP includes an Early-Career Partnership Option across all award mechanisms, designed to:

• Encourage collaboration between established and emerging investigators.

• Provide two individual awards under a single project with separate budgets.

• Support career development while increasing research capacity.

What is the timeline to apply and when would I receive funding?

Pre-announcement release: February 17, 2026

1. Formal Funding Opportunity Announcements (FOAs): To be posted on Grants.gov and CDMRP as soon as they are finalized. Pre-applications and full application deadlines will be included in those FOAs.

2. Funding start: After application review and award selection (dates will be provided in individual FOAs).

Where does this funding come from?

Funding is authorized by the FY26 Defense Appropriations Act, which appropriated funds to the CDMRP for a wide range of research programs, including the TSCRP.

Who is eligible to apply?

Eligibility will be defined in each FOA, but CDMRP programs typically allow:

• Independent investigators at all career levels.

• Clinical and translational researchers with relevant expertise.

• Multiple institutional types (academic, nonprofit, clinical).

(Final eligibility criteria will appear in the specific FOAs once posted.)

What companies and projects are likely to win?

Competitive applications typically:

• Align clearly with one or more of the TSCRP focus areas.

• Show strong scientific rationale and potential for impact on TSC care or understanding.

• Include translational significance or potential to advance clinical outcomes.

Are there any restrictions I should know about?

• The pre-announcement is not a guarantee of funding or a FOA; investigators cannot submit applications based on it alone.

• Formal submission instructions, eligibility, and restrictions will be defined in forthcoming FOAs.

How long will it take me to prepare an application?

Time needed varies by project, but standard CDMRP FOAs often allow several weeks to months for:

• Letter of intent (if required).

• Pre-application submission.

• Full application preparation.

Tip: Begin early by reviewing past TSCRP FOAs and planning collaborative teams, hypotheses, and preliminary data.

How can BW&CO help?

If you need assistance with strategy, positioning against TSCRP priorities, or full proposal writing support, BW&CO can:

• Align your research aims to TSCRP’s priority areas.

• Draft compelling abstracts and narratives tailored to CDMRP review criteria.

• Provide budget and compliance support based on CDMRP rules.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Spinal Cord Injury Research Program (SCIRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

On February 17, 2026, the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) released the Spinal Cord Injury Research Program (SCIRP) anticipated funding opportunities for Fiscal Year 2026 (FY26), providing researchers with key priorities and award mechanisms to plan applications ahead of full Funding Opportunity Announcements. This pre-announcement outlines the SCIRP’s research goals and award structures, including a strong emphasis on clinical, translational, and investigator-initiated research in spinal cord injury. Final Funding Opportunity Announcements with deadlines will be posted on Grants.gov once available.

How much funding would I receive?

The pre-announcement specifies award maximums for each mechanism (total costs, including direct and indirect):

• Clinical Trial Award

  • Single PI: up to $4.8M over 4 years

  • Early-Career Partnership Option: up to $4.96M over 4 years

• Clinical Translation Research Award

  • Single PI: up to $2.0M over 3 years

  • Early-Career Partnership: up to $2.16M over 3 years

• Translational Research Award

  • Single PI: up to $2.0M over 3 years

  • Early-Career Partnership: up to $2.16M over 3 years

• Investigator-Initiated Research Award

  • Single PI: up to $800,000 over 3 years

  • Early-Career Partnership: up to $960,000 over 3 years

What could I use the funding for?

Funding supports research that advances spinal cord injury (SCI) understanding, treatment, and care across four major areas:

• Acute Injury Intervention

  • Develop and test interventions to protect spinal cord tissue after injury with measurable neurological benefit.

• Secondary Health Effects

  • Research interventions addressing long-term consequences of SCI across the lifespan.

• Psychosocial Issues

  • Test strategies for promoting psychosocial well-being tailored to people with SCI and their families/care partners.

• Rehabilitation and Regeneration

  • Advance rehabilitation strategies and regenerative/neuroplastic approaches for improved functional recovery.

Are there any additional benefits I would receive?

FY26 SCIRP includes an Early-Career Partnership Option across all award mechanisms, designed to:

• Encourage collaboration between established and emerging investigators.

• Provide two individual awards under a single project with separate budgets.

• Support career development while increasing research capacity.

What is the timeline to apply and when would I receive funding?

Pre-Announcement (released): February 17, 2026.

Next Steps:

• Full Funding Opportunity Announcements (FOAs) will be posted on Grants.gov and contain specific pre-application and application deadlines.

• Applicants must submit a pre-application (via eBRAP) prior to the full application.

• Funding awards start after review and final selection dates in the FOAs. (Exact dates not yet published.)

Where does this funding come from?

SCIRP is part of the CDMRP, a Department of Defense research portfolio funded through the Defense Appropriations Act. For FY26, the CDMRP received appropriations to fund 34 research programs including SCIRP.

Who is eligible to apply?

Eligibility varies by award mechanism, but in general:

• Independent investigators at all career levels are eligible for single PI awards.

• Early-Career Partnership Option requires one early-career investigator meeting defined experience criteria.

Specific eligibility criteria and organizational requirements will be detailed in the FOAs. al relevance.

What companies and projects are likely to win?

Projects most competitive will:

• Directly address one or more SCIRP priority research areas.

• Demonstrate scientific impact, innovation, and relevance to SCI outcomes.

• Include clear paths to clinical or translational impact (as specified by mechanism).

• (For Early-Career Partnership) show strong mentorship and collaborative planning.

Are there any restrictions I should know about?

• Pre-applications are required before full applications.

• All research must conform to final FOA requirements once released.

• Funding opportunity terms, budgets, eligible costs, and indirect cost policies will be specified in FOAs.

How long will it take me to prepare an application?

Preparation time depends on research maturity and team readiness, but investigators should factor in:

• Time to align research with SCIRP priorities.

• Drafting a competitive pre-application (often weeks before FOA deadlines).

• Preparing full application (including budgets, human subjects, partnerships).
  (SCIRP pre-announcement is intended to give applicants advance planning time.)

How can BW&CO help?

If you need assistance with strategy, positioning against SCIRP priorities, or full proposal writing support, BW&CO can:

• Align your research aims to SCIRP’s priority areas.

• Draft compelling abstracts and narratives tailored to CDMRP review criteria.

• Provide budget and compliance support based on CDMRP rules.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Rapid Stabilization and Barcoding Challenge – Defense Threat Reduction Agency (DTRA)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Defense Threat Reduction Agency (DTRA) is seeking U.S.-based industry, academic, and nonprofit organizations to prototype a fully integrated, handheld system that eliminates cold-chain requirements for chemical and biological samples. The system must stabilize molecules at ambient conditions, integrate barcode-based lifecycle tracking, and automate sampling. Applications are due March 9, 2026 at 1:00 PM.

How much funding would I receive?

Funding Award Size: $300K to $5 Million+

Awards will be made under the ONIX OTA in coordination with ACC-RI. Specific award size will depend on scope and proposed effort.

What could I use the funding for?

Overall Objective

DTRA is seeking to develop Rapid Stabilization and Barcoding prototypes and test these for operational relevancy. This effort aims to research and develop innovative stabilization technologies that leverage custom stable porous capillary-fibrous scaffolds, providing high permeability and improved surface-area-to-volume ratios to enhance binding and stabilization efficiency of molecules and reagents, ultimately ensuring assay consistency.  Systems should improve utility of vitrification under vacuum and rapid drying of molecules and reagents, supporting the general services for years to come.  Alternatives to lyophilization may include methodologies that avoid freezing and/or boiling of molecules or reagents, prevent solution crystallization, and eliminate the use of liquid nitrogen for storage.

To support rapid and reliable sample stabilization in field environments, the system must also incorporate robust barcode-based sample tracking.

Problem Statement

Current reliance on cold-chain logistics places a burden on the general forces due to reagents and sample degradation. Further, sample tracking approaches often rely on handwritten labels, inconsistent naming conventions, and manual tracking; all of which introduce vulnerabilities such as mislabeling and loss of chain-of-custody. This effort seeks industry solutions that will result in rapid stabilization and barcoding.

Desired Solution

·       Sustain structural stability of chemical and biological molecules for storage at room temperature for at least 12 months, in various environmental conditions.

·       Perform in a wide variety of environmental MIL STD 810H conditions, ranging from -20 ℃ to 55 ℃ and 10-95% relative humidity.

·       Mitigate degradation risks from sample matrix complexities.

·     Have a simple and standardized workflow.  End-user training should be completed within one hour, with minimal operational complexity and no specialized technical expertise required.

·       Complete the entire vitrification process, from sample collection to final stabilization, within 30 minutes.

·       Require low power, enabling operation in austere and off-grid environments.  If a battery is necessary, the system should utilize lightweight solid-state batteries.

·       Be handheld and portable, preferably less than 30 cm x 15 cm x 15 cm and weigh less than 10 lbs. (4.5 kg) is the preferred end goal.

·       Remain low in costs, at approximately $100 or less for reusable systems or $25 or less for single-use systems when purchased in quantity.

·       Integrate automated sample collection mechanisms that enable consistent and repeatable sampling.

·       Read 1D and 2D barcodes on labels, vials, and screens.

·       Be MIL STD 810H compliant for shock, dust, humidity, and temperature extremes.

·       Support Bluetooth or Wi-Fi options for direct integration with field instruments.

·       Have a minimum 12 hours of continuous and wireless scanning.

Are there any additional benefits I would receive?

Beyond the direct funding award, there are meaningful indirect benefits:

Government Validation and Credibility:
Selection by DTRA RD-CB signals strong technical credibility in chemical and biological defense technologies, which can accelerate follow-on DoD opportunities.

Enhanced Market Visibility:
Awardees gain visibility within the CBRN defense ecosystem and may benefit from broader recognition through DoD networks.

Dual-Use Positioning:
Technologies that eliminate cold-chain requirements and improve sample tracking have applications in biodefense, public health, field diagnostics, and industrial biosurveillance.

Nondilutive Capital:
OTA-based funding allows you to mature hardware and IP without equity dilution, strengthening valuation and exit potential.

What is the timeline to apply and when would I receive funding?

• Submission Deadline: March 9, 2026 at 1:00 PM

• Anticipated Down-Select: 30–45 days after posting

Specific award start dates are not listed, but selection and award are expected shortly after down-select.

Where does this funding come from?

Funding is provided by the Defense Threat Reduction Agency (DTRA), Research and Development, Chemical and Biological Technologies Directorate (RD-CB), in support of the Capability Program Executive for Chemical, Biological, Radiological, Nuclear Defense.

Awards will be made under the ONIX OTA in coordination with ACC-RI.

Who is eligible to apply?

• U.S.-based industry organizations

• U.S.-based academic institutions

• U.S.-based nonprofit organizations

What companies and projects are likely to win?

Based on the scoring rubric, competitive proposals will demonstrate:

• A technically viable stabilization methodology using porous capillary-fibrous scaffolds (or alternatives that prevent freezing, boiling, crystallization, and eliminate liquid nitrogen dependency)

• Full integration of 1D/2D barcode tracking with LIMS compatibility

• Reliable automated sampling with reduced operator involvement

• Demonstrated ability to meet 12-month room-temperature stability across MIL STD 810H conditions

• Clear milestones, realistic deliverables, credible past performance, and well-justified costs/IP strategy

Are there any restrictions I should know about?

• Must be U.S.-based.

• Must comply with MIL STD 810H environmental requirements.

• System must meet specific SWaP-C targets and defined cost thresholds.

• Submission length limited to 2–10 pages (plus required company and past performance pages).

• Submission required via GoColosseum platform.

How long will it take me to prepare an application?

Given the 2–10 page technical response, plus company and past performance pages and milestone-based cost structure, most teams should expect approximately 2–4 weeks to prepare a competitive submission, depending on readiness of technical concept and prior materials.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the opportunity here.

CDMRP: Arthritis Research Program (ATRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Arthritis Research Program (ATRP) has released its anticipated funding opportunities for Fiscal Year 2026, funded through the Department of Defense’s FY26 Defense Appropriations Act and managed by the CDMRP. This pre-announcement is meant to help investigators prepare competitive proposals ahead of the official Funding Opportunity Announcements (FOAs). Deadlines for pre-applications and full applications will be included in the upcoming FOAs on Grants.gov once released.

How much funding would I receive?

While the total program budget for ATRP isn’t specified in the pre-announcement itself, the FY26 DoD appropriations provide funding for the ATRP as part of a broader portfolio that includes a ~$10 M allocation for arthritis research.

Per award (anticipated levels):

• Clinical Research Award

  • Research Level 1: Up to $1.3 M total costs over up to 4 years.

  • Research Level 2: Up to $3.25 M total costs over up to 4 years.

• Translational Research Award

  • Up to $800,000 total costs over up to 3 years.
    All awards count direct + indirect costs.

What could I use the funding for?

Funding is structured to support clinically relevant arthritis research:

Prevention & Early Diagnosis

• Identify factors predicting disease onset/progression

• Develop technologies or solutions for arthritis prevention.

Treatment & Burden Mitigation

• Topic 1: Evaluate interventions or strategies that alleviate pain/symptoms, improve function, address psychosocial factors, comorbidities, or pathologic disease burden.

• Topic 2: Develop new solutions targeting similar multifactorial elements of arthritis.

Translated into potential research areas:

• Pilot studies or full clinical trials (clinical research)

• Translational projects moving discoveries toward clinical application (without supporting clinical trials)

Are there any additional benefits I would receive?

• Being part of a CDMRP program provides two-tier review with both scientific and programmatic relevance evaluation (via eBRAP/Grants.gov processes).

• Opportunities to influence care and policy with clinically actionable outputs.

• Access to broader CDMRP support resources and network.

What is the timeline to apply and when would I receive funding?

• This is a pre-announcement only. Formal FOAs with pre-application and full application deadlines will be posted to Grants.gov and eBRAP later.

• Funding timeline (award start to end) aligns with award type (up to 3–4 years).

Where does this funding come from?

Funding comes from the FY26 Defense Appropriations Act, via the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP), managed through the Defense Health Agency Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

• Independent investigators at all academic levels or equivalents can apply for all award types.

• Clinical awards expect research aligned with program focus areas.

• Translational awards require preliminary data and aim to move findings toward clinical relevance.

What companies and projects are likely to win?

Likely competitive applicants will:

• Address prevention, early diagnosis, treatment efficacy, or multifactorial burden mitigation of arthritis.

• Show strong preliminary data, especially for translational and clinical research.

• Demonstrate clinical relevance and potential to improve patient outcomes.

• Include multidisciplinary teams with community collaborators (patients/care partners) for applicability.

Are there any restrictions I should know about?

• Pre-announcement is not a funding obligation or contract — final requirements and eligibility criteria will be defined in FOAs.

• Clinical trials require appropriate planning and justification.

• Applications for clinical research must include relevant preliminary/published data.

How long will it take me to prepare an application?

• Preparation timelines vary by mechanism:

  • Clinical Research Awards may take months to draft due to data, design, and collaborator requirements.

  • Translational Awards also require solid preliminary evidence.

  • Plan ahead for eBRAP pre-applications and revision cycles before full submission. (Recommended: map to FOA deadlines once published.)

How can BW&CO help?

BW&CO could support you by:

• Interpret the FOA once published and align your research to program priorities.

• Develop competitive research and budget narratives.

• Coordinate pre-application eBRAP submission and compliance checks.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Amyotrophic Lateral Sclerosis Research Program (ALSRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP Amyotrophic Lateral Sclerosis Research Program (ALSRP) released a pre-announcement on February 13, 2026 outlining anticipated FY26 funding opportunities. This pre-announcement is not a funding solicitation — rather, it gives investigators advanced insight to begin planning and developing ideas ahead of the full Funding Opportunity Announcements (FOAs) to be posted later on Grants.gov and eBRAP. Actual deadlines (pre-application and application) will only be available in the final FOAs once they are released — this pre-announcement does not set them.

How much funding would I receive?

The pre-announcement lists maximum allowable funding by mechanism (total costs):

• Clinical Outcomes and Biomarkers Award: up to $1.0M over up to 3 years

• Pilot Clinical Trial Award: up to $2.8M over up to 3 years

• Therapeutic Development Award: up to $2.0M over up to 3 years

• Therapeutic Idea Award: up to $840,000 over up to 2 years

Final program appropriations for ALSRP in FY26 are part of the CDMRP portfolio; historically this has been in the tens of millions — for example, FY25 saw ~$40M allocated.

What could I use the funding for?

Funding supports distinct research areas that align with ALS therapeutic development and clinical impact:

A) Clinical Outcomes and Biomarkers Award

• Develop/validate clinical outcomes or biomarkers to improve ALS clinical trials.

• May include clinician-, observer-, or patient-reported measures and performance outcomes.

• Supports non-interventional biospecimen/data collection (may be parallel to ongoing trials).

B) Pilot Clinical Trial Award

• Early-stage clinical trials with therapeutic efficacy or biological outcome measures.

• Therapeutic interventions must incorporate biomarker-driven designs.

C) Therapeutic Development Award

• Preclinical validation / IND-enabling studies of ALS therapeutics with proof-of-concept data.

• Biomarker development included to support future clinical design.

D) Therapeutic Idea Award

• Novel, high-risk/high-gain hypothesis-driven research aimed at ALS therapy discovery.

• Must include biomarker rationale relevant to eventual clinical trials.

Are there any additional benefits I would receive?

The pre-announcement itself does not specify additional benefits such as training supplements, travel, or workshops. Historically, CDMRP programs may offer resources like investigator workshops and programmatic feedback, but this will be detailed in the final FOAs.

What is the timeline to apply and when would I receive funding?

• Current status: This is a pre-announcement — exact pre-application and application deadlines will be in the forthcoming FOAs on Grants.gov.

• Recommendation: Begin planning now; monitor CDMRP and Grants.gov for FOA release.

• Funding start dates and award notifications will depend on those FOA schedules.

Where does this funding come from?

The ALSRP is funded through the FY26 Defense Appropriations Act and administered by the Congressionally Directed Medical Research Programs under the Defense Health Agency Research and Development / Medical Research and Development Command.

Who is eligible to apply?

Eligibility across mechanisms typically includes independent investigators at all academic levels, or equivalent. Specific institutional eligibility and PI requirements will be defined in the FOAs.

What companies and projects are likely to win?

Competitive applicants are those who:

• Align closely with the intent and scope of each mechanism (clinical outcomes, biomarker rigor, early trials, or therapeutic innovation).

• Propose biomarker-driven strategies that clearly inform later-stage clinical development.

• Build strong community collaboration plans, such as including patient/care partner perspectives.

Final criteria will be in FOA evaluation sections.

Are there any restrictions I should know about?

Restrictions noted in the pre-announcement include:

• Clinical Outcomes and Biomarkers Award does not support interventional clinical trials.

• Therapeutic Idea Award proposals focusing primarily on basic pathophysiology without therapeutic development are not in scope.

• All mechanisms require preproposal submission via eBRAP; full applications are by invitation only.

How long will it take me to prepare an application?

The prep time depends on research maturity, but competitive proposals will typically require:

• Development of a biomarker plan or clinical trial design where applicable.

• Preliminary data for Therapeutic Development scale.

• Engagement of community collaborators early.

Start now — ahead of FOA release — to coordinate team, core facilities, preliminary work, and collaborations.

How can BW&CO help?

BW&CO could support you by:

• Interpreting the final FOAs when released with deadlines and criteria.

• Drafting and refining preproposals and full applications for each mechanism.

• Crafting compelling narrative aligned with CDMRP’s two-tier review process.

• Identifying required biospecimen, clinical, and biomarker components to strengthen impact.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Ovarian Cancer Research Program (OCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) has released a pre-announcement for the FY26 Ovarian Cancer Research Program (OCRP), outlining anticipated funding opportunities. This pre-announcement allows investigators to begin planning competitive proposals ahead of the formal Funding Opportunity Announcements (FOAs) that will be posted on Grants.gov. Applications will be required to address one or more OCRP priority areas, including novel therapies, early detection, quality of life/survivorship, prevention, and basic ovarian cancer biology. Deadlines for pre-applications and full applications will be provided in the FOAs once published.

How much funding would I receive?

Final funding levels and award amounts will be defined in the FY26 FOAs; estimates from similar past OCRP mechanisms include:

• Clinical Trial Award: Up to $2.8M total costs (max) over up to 4 years

• Investigator-Initiated Research Award: Up to $1.05M (single PI) or $1.4M (Partnering PI) over 4 years

• Ovarian Cancer Academy – Early-Career Investigator Award: Up to $1.125M total costs over 4 years

• Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award: Up to $1.4M total costs over 4 years

• Pilot Award: Up to $350,000 total costs over 2 years

These figures reflect anticipated ceilings based on FY25 mechanisms and are subject to confirmation in the FY26 FOAs.

What could I use the funding for?

Funding supports ovarian cancer research aligned with program priorities:

• Clinical trials and translational research

• Proof-of-concept through early phase studies with potential to impact patient care.

• High-impact investigator-driven research

• Basic through translational research (excluding clinical trials under certain mechanisms).

• Early-career investigator development and mentoring

• Interactive training academies for research and clinical trial skills.

• Innovation and preliminary discovery

• Pilot research to generate data for larger projects.

Are there any additional benefits I would receive?

Beyond funding, OCRP mechanisms like the Academy awards provide:

• Mentoring and networking opportunities for early-career researchers.

• Structured professional development through virtual academy experiences.

• Enhanced visibility within the ovarian cancer research community.

What is the timeline to apply and when would I receive funding?

• Application deadlines: Not yet published in the FY26 pre-announcement; FOAs with specific dates will be posted on Grants.gov once released.

• Pre-application & full application deadlines: Will be included in FOAs.

• Award start dates: After review and programmatic selection; typical NIH/DOD timing suggests awards may begin late in FY26 or early FY27, depending on FOA timelines.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act as part of the DoD’s CDMRP portfolio. OCRP is one of the congressionally directed research programs funded by federal appropriations.

Who is eligible to apply?

Eligibility typically aligns with CDMRP standards:

• Independent investigators (Assistant Professor level or equivalent and above) for most mechanisms.

• Early-career investigators for Academy awards (within defined years of training completion).

• Postdoctoral and clinical fellows for Pilot awards.

Specific eligibility criteria will be detailed in the FY26 FOAs.

What companies and projects are likely to win?

Competitive submissions will:

• Address one or more OCRP areas of emphasis (e.g., early detection, novel therapies, quality of life).

• Demonstrate clinical relevance or strong scientific rationale.

• Present clear pathways to impact ovarian cancer outcomes.

• Align with funding mechanism intent (e.g., ECI development for academy awards).

Projects with rigorous design, transformative potential, and relevance to patient populations are most competitive.

Are there any restrictions I should know about?

Examples based on past OCRP announcements:

• Some mechanisms do not support clinical trials (e.g., Investigator-Initiated Research Award, Pilot Award).

• Applicants may only receive one award per funding cycle from certain mechanisms.

• Pre-application submission is required before full application.

• Investigator eligibility windows apply for early-career awards.

Full restrictions will be in the FY26 FOAs.

How long will it take me to prepare an application?

Preparation time depends on mechanism, but investigators should plan for:

• 8–12 weeks to develop scientific aims, budgets, and letters.

• Additional time if data generation or collaborations are needed.

Starting now will position teams to respond quickly when FOAs are released.

How can BW&CO help?

BW&CO can:

• Interpret OCRP priority areas and align research plans.

• Draft compelling proposals and strong scientific narratives.

• Coordinate submission timelines and compliance packages.

• Support budget and team planning for each mechanism.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

DIU: Runway Independent Maritime & Expeditionary Strike (RIMES)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This is a DIU Commercial Solutions Opening (CSO) that invites companies with novel unmanned aerial systems (UAS) capable of providing long-range strike support for naval surface combatants—without relying on large runways or flight decks—to submit a solution. It is a fast, flexible path to a prototype Other Transaction (OT) award that could potentially lead to follow-on production contracts across the U.S. Department of Defense. Proposals are due February 27, 2026 at 23:59:59 US/Eastern Time.

How much funding would I receive?

The DIU CSO does not specify a fixed award amount on the posting. Instead, selected vendors typically negotiate a prototype Other Transaction (OT) agreement. Funding levels vary based on solution complexity and scope, and successful prototype awards can lead to larger follow-on production arrangements.

What could I use the funding for?

You may propose funding for:

• Technical development of a long-range UAS capability that meets the challenge criteria

• Prototyping of vehicle hardware, autonomy software, and integration with naval systems

• Test, evaluation, and demonstration efforts

• Integration and safety risk reduction activities

• Personnel, materials, subcontractors, and other direct costs aligned with system delivery and prototype execution

DIU’s focus is mission-relevant prototyping that can be transitioned rapidly to DoD users.

Are there any additional benefits I would receive?

If your prototype is successful:

• You may be considered for follow-on production contracts or agreements that do not require further competitive procedures, under 10 U.S.C. 4022(f).

• DIU’s CSO process provides strategic exposure and faster contracting than traditional DoD pathways.

What is the timeline to apply and when would I receive funding?

Submission Deadline: February 27, 2026 at 23:59:59 US/Eastern — submit solution brief by this time.

After submission:

• DIU reviews briefs and may invite you to pitch or submit a full proposal.

• Prototype OT awards are typically executed weeks to a few months after selection, depending on evaluations and negotiations.

Where does this funding come from?

This solicitation is run by the Defense Innovation Unit (DIU) — a Department of Defense organization that accelerates commercial technology adoption for national security missions. It uses Other Transaction Authority (OTA) to award prototype agreements directly to commercial tech companies.

Who is eligible to apply?

• U.S. and foreign owned businesses are generally eligible; eligibility specifics are governed by the broader CSO requirements.

• Companies must register in SAM.gov and obtain a CAGE code prior to award if not already registered.

• A CMMC Level 2 (Self) cybersecurity posture is required before award.

DIU encourages commercial entities of all sizes — including first-time defense contractors — to submit solutions.

What companies and projects are likely to win?

Strong candidates will offer a UAS that:

• Operates without runways or large flight decks

• Has ≥1400 NM one-way range with a ~1000-lb payload of standard naval munitions

• Integrates with existing combat systems

• Demonstrates mission autonomy and resilience in contested environments

• Offers cost-effective, maintainable, and scalable approaches

• Supports rapid prototyping and field demonstration within 12 months

Projects that show technical maturity, clear operational benefit, and transition readiness are most competitive.

Are there any restrictions I should know about?

• Solutions must meet DIU CSO format and content requirements, typically not exceeding five pages or fifteen slides.

• CMMC Level 2 (Self) compliance is required before award.

• Any award will include compliance with applicable laws such as Section 889 NDAA requirements.

How long will it take me to prepare an application?

• A compliant Solution Brief should take a few weeks of focused effort to develop, including company overview, technical description, risk assessment, and linkage to challenge attributes.

• For competitive positioning, start well before the deadline to refine mission relevance and prototype feasibility.

How can BW&CO help?

BW&CO can help you:
• Translate your technical capabilities into a competitive DIU solution brief.
• Strategize on Line of Effort selection and demo readiness.
• Prepare compliance documentation and security coordination plans.
• Draft a high-impact live demonstration plan that aligns with DIU and DoD expectations.

How much would BW&CO Charge?

We have an hourly rate to strategize, review, and edit applications of $250.

Additional Resources

Review the solicitation here.

DIU: Counter UAS Sensing for Homeland and Mobile Defense

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Defense Innovation Unit (DIU) seeks commercial sensing solutions to detect, track, and classify small unmanned aerial systems (sUAS) for fixed homeland defense and mobile tactical use. This Commercial Solutions Opening (CSO) is urgent due to evolving UAS threats, and responses are due by February 26, 2026 at 23:59:59 US Eastern Time. Selected companies may be invited to a Phase 2 live demonstration at Yuma Proving Ground (AZ) in Spring 2026 — at the company’s expense — making quick readiness and regulatory compliance essential.

How much funding would I receive?

DIU does not list a specific award amount on the submission page. As a CSO, funding typically depends on the solution’s relevance and negotiation between DIU, the DoD sponsor, and the vendor — often structured as an Other Transaction (OT) prototyping agreement. Follow-on production awards can be significantly larger if the prototype is successful.

What could I use the funding for?

Prototypes should deliver scalable, survivable, life-saving sUAS sensing capabilities in two categories:
• Line of Effort 1 — Homeland Defense Sensing:

• Persistent fixed-site sensing near population centers and congested airspace.

• Must include a radar sensor with high-performance detection, tracking, and classification.
  • Line of Effort 2 — Mobile Tactical Sensing:

• Resilient, low-signature systems that operate stationary and on-the-move in GNSS-denied or contested environments.
  Proposals must demonstrate technical performance, integration paths, and operational readiness.

Are there any additional benefits I would receive?

• Rapid engagement with the U.S. Department of Defense through DIU’s CSO process.
• Potential transition to follow-on production contracts without further competition if your prototype meets success criteria under 10 U.S.C. 4022(f) authority.
• Exposure to DoD partners and Program Managers at demonstration events (e.g., Yuma Proving Ground).

What is the timeline to apply and when would I receive funding?

• Solution briefs due: February 26, 2026 @ 23:59:59 US Eastern Time.
• Phase 2 live demonstration: Planned for Spring 2026 at Yuma Proving Ground, AZ.
Funding awards are typically announced after Phase 1 evaluation and negotiation, which can occur within DIU’s standard 60-90 day CSO window once a solution is selected for full proposal submission.

Where does this funding come from?

This project is funded by the U.S. Department of Defense (DoD) and administered by the Defense Innovation Unit (DIU) through its Commercial Solutions Opening (CSO) process, leveraging Other Transaction Authority (OTA).

Who is eligible to apply?

Any commercial entity or individual with a mature sensing solution or applicable commercial-ready technology can respond. DIU encourages both established defense contractors and nontraditional vendors to submit.

What companies and projects are likely to win?

Competitively favored proposals will:
• Address either or both LOEs fully and clearly.
• Demonstrate proven sensing performance (e.g., range, tracking, classification).
• Provide integration paths with DoD systems and readiness for live demonstration.
• Be commercially mature or near production — especially for Homeland Defense sensing.

Are there any restrictions I should know about?

• If selected for live demonstrations, companies must coordinate security protocols (varies for U.S. vs. non-U.S. citizens) and supply a DD Form 1494 with the Phase 1 proposal.

• Proposals must comply with DoD cybersecurity frameworks (e.g., RMF and ATO).

• Nontraditional defense contractors may enable faster OT awards; traditional contractors might need a cost share per DIU CSO rules.

How long will it take me to prepare an application?

Expect 2–6 weeks to prepare a compelling solution brief depending on:
• Technical readiness of your system.
• Teaming arrangements and integration plans.
• Supporting data on detection performance.
• Required compliance forms (e.g., DD 1494).

How can BW&CO help?

BW&CO can help you:
• Translate your technical capabilities into a competitive DIU solution brief.
• Strategize on Line of Effort selection and demo readiness.
• Prepare compliance documentation and security coordination plans.
• Draft a high-impact live demonstration plan that aligns with DIU and DoD expectations.

How much would BW&CO Charge?

We have an hourly rate to strategize, review, and edit applications of $250.

Additional Resources

Review the solicitation here.

Air Force Cryptologic Office (AFCO) Commercial Solutions Opening (CSO)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Air Force Cryptologic Office (AFCO) is actively seeking innovative commercial technologies to support U.S. Air Force cyberspace intelligence, electromagnetic warfare, information operations, and multi-domain operations. This Commercial Solutions Opening (CSO) is designed to move fast, fund mature technologies applied in novel ways, and support field demonstrations—ideally within one year.

How much funding would I receive?

AFCO expects to make individual awards ranging from:

• $50,000 to $50,000,000 over the full period of performance

These amounts are not strict limits. Proposals over $15,000,000 must include phased options that allow for incremental funding. All awards are subject to the availability of funds.

What could I use the funding for?

Funding may be used to develop, demonstrate, test, or deploy innovative commercial technologies aligned with AFCO’s mission areas. Proposals must address one or more of the following capability areas:

AFCO-CM-001, ELECTROMAGNETIC WARFARE (EW)

• Electromagnetic attack, support, and protection

• EW data fusion and advanced signal processing

• Cognitive EW and AI/ML-enabled techniques

• EW battle management and waveform generation

AFCO-CM-002, INFORMATION OPERATIONS (IO)

• Technologies that affect adversary decision-making

• Capabilities targeting informational, physical, or cognitive dimensions

• Generative AI or autonomous AI applied to the information environment

AFCO-CM-003, Electromagnetic Digital Communications

• Free-space and space-based digital communications

• Access, denial, disruption, degradation, deception, or destruction of communications

• Novel approaches emphasizing extensibility over single-purpose solutions

AFCO-CM-004, Multi-Domain Innovation

• Integrated effects across EW, cyberspace, ISR, and information operations

• Automated and synchronized multi-domain operational capabilities

Are there any additional benefits I would receive?

In addition to funding, successful companies may receive:

• Direct engagement with Air Force technical and operational stakeholders

• Opportunities for follow-on contracts or Other Transactions (OTs)

• Potential multi-year periods of performance (up to five years)

• A clear pathway from prototype to operational relevancest Proposal and SOW).

What is the timeline to apply and when would I receive funding?

• Phase I: Quad Chart and White Paper may be submitted at any time before September 30, 2026

• Phase II: Only by invitation from the Contracting Officer

• Proposal preparation window (Phase II): 30 calendar days from invitation

• Expected contract start: Approximately 90 days after proposal submission

Period of performance:

• Typically 1–5 years, with exceptions considered based on maturity or need

Where does this funding come from?

Funding is provided by the Air Force Cryptologic Office (AFCO), Cyberspace ISR and Multi-Domain Innovation Division, under the U.S. Department of the Air Force.

Awards may be issued as:

• Firm Fixed Price (FFP) contracts

• Fixed Price Incentive (FPI) contracts

• Other Transactions (OTs) under 10 U.S.C. §2371bal Medicines).

Who is eligible to apply?

Eligible applicants include:

• U.S.-based commercial companies

• Small businesses and non-traditional defense contractors

• Companies offering commercial items, technologies, or services

To receive an award, companies must:

• Be registered in SAM.gov

• Be considered responsible under FAR Part 9.1

• Meet any security clearance requirements if proposing classified work

What companies and projects are likely to win?

Successful proposals typically:

• Apply mature technologies in novel ways

• Demonstrate clear relevance to AFCO mission needs

• Support field demonstrations within one year (ideally)

• Offer measurable improvements to operational effectiveness

• Align with open architecture approaches (e.g., SOSA, OMS/UCI, modular software/hardware)

Are there any restrictions I should know about?

Yes. Key restrictions include:

• All submissions must be commercial solutions

• Classified submissions require prior coordination

• Proposals exceeding page limits will not be evaluated

• Intellectual property assertions must follow DFARS requirements

• AFCO may partially fund, incrementally fund, or decline any proposal

How long will it take me to prepare an application?

Typical preparation times:

• Phase I (Quad Chart + White Paper): 1–3 weeks

• Phase II (if invited): 30 calendar days

The Phase II submission includes a technical proposal, statement of work, and detailed pricing.

How can BW&CO help?

BW&CO can help you:

• Rapidly assess fit against AFCO’s priority areas

• Shape your Quad Chart and White Paper for evaluator clarity

• Position your technology for Phase II invitation

• Translate technical capabilities into mission-aligned value propositions

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

DIU - Containerized Autonomous Drone Delivery System (CADDS)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

DIU’s Commercial Solutions Opening (CSO) solicitation PROJ00637 — Containerized Autonomous Drone Delivery System (CADDS) seeks innovative commercial solutions to enable rapid deployment and autonomous operation of large numbers of unmanned aerial systems (UAS) from containerized platforms. This opportunity closes February 17, 2026 at 23:59:59 US Eastern Time — urgent submission recommended.

How much funding would I receive?

The exact award amount is not specified online. DIU typically awards prototype contracts under Other Transaction (OT) authority, with budgets determined during negotiation based on solution scope and DoD partner need. Follow-on production contracts may be possible if the prototype is successful.

What could I use the funding for?

This solicitation is looking for solutions that:

• Enable rapid, large-scale UAS deployment from containerized platforms.

• Automate storage, launch, recovery, and refit for multi-agent systems.

• Provide rapid transport and emplacement using military/commercial vehicles.

• Support resilient command and control interfaces and open architecture integration.

• Reduce human operator burden and minimize required crew size.

You’d be expected to demonstrate capabilities within ~90 days of award.

Are there any additional benefits I would receive?

• Potential follow-on production contracts without additional competition under 10 U.S.C. § 4022 if the prototype succeeds.

• A fast-moving path into Department of Defense fielding and contracting.

What is the timeline to apply and when would I receive funding?

• Proposal Deadline: February 17, 2026 @ 23:59:59 US/Eastern.

• DIU typically reviews solution briefs first, then invites selected teams to pitch/submit full proposals (often within ~30 days).

• Prototype projects are generally expected to be demonstrable within ~90 days of award.

Where does this funding come from?

DIU is part of the U.S. Department of Defense, focused on accelerating commercial tech adoption for defense applications. Funding is administered under Other Transaction (OT) authority — a flexible contracting approach outside traditional FAR rules.

Who is eligible to apply?

U.S. and international vendors are eligible to respond.

1. To use an OT agreement, requirements of 10 U.S.C. § 4022 must be satisfied (e.g., contributions by nontraditional defense contractors, small business participants, or cost sharing).

What companies and projects are likely to win?

Competitive submissions will:

• Clearly align with rapid autonomous UAS deployment at scale.

• Demonstrate modularity, open architecture, and operational utility.

• Show ability to reduce human operator burden and handle austere environments.

• Present clear pathway to meet the ~90-day demonstration target.

Are there any restrictions I should know about?

Compliance with Section 889 of the John S. McCain NDAA is required for award.

1. IP is generally retained by the company, with negotiated DoD use rights.

2. OT agreements have specific cost-sharing and contractor status rules under 10 U.S.C. § 4022.

How long will it take me to prepare an application?

• Solution briefs are typically ~5 pages (or ~15 slides) and can be prepared in 1–3 weeks with focused effort.

• Full proposals (if invited) will require detailed technical and project execution plans.

How can BW&CO help?

BW&CO can assist with:

• Crafting solution briefs that clearly align with DIU’s mission and review criteria.

• Developing full OT proposals with technical, cost, and operational plans.

• Strategizing for rapid prototype demonstration and DoD transition pathways.

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.